Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Will CSF biomarkers guide future therapeutic decisions in multiple sclerosis?
Alarmin' Immunologists: IL-33 as a Putative Target for Modulating T Cell-Dependent Responses.
Sex Chromosome Complement Influences Functional Callosal Myelination.
Patients with neuromyelitis optica have a more severe disease than patients with relapsingremitting multiple sclerosis, including higher risk of dying of a demyelinating disease.
Peripartum depression in parents with multiple sclerosis and psychiatric disorders in children.
Recombinant Human Myelin-Associated Glycoprotein Promoter Drives Selective AAV-Mediated Transgene Expression in Oligodendrocytes.
Acute Bilateral Optic Neuritis in Active Ankylosing Spondylitis.
Promotion of Remyelination by Sulfasalazine in a Transgenic Zebrafish Model of Demyelination.
The role of noninvasive and invasive diagnostic imaging techniques for detection of extra-cranial venous system anomalies and developmental variants.
Tumefactive multiple sclerosis and fingolimod: Immunotherapies and unintended consequences.
Sonic hedgehog promotes generation and maintenance of human forebrain Olig2 progenitors.
The incidence and prevalence of neuromyelitis optica: a systematic review.
Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice.
Validation of mood measures for people with multiple sclerosis.
Protective effect of a germline, IL-17-neutralizing antibody in murine models of autoimmune inflammatory disease.
Increased Circulating Levels of Vitamin D Binding Protein in MS Patients.
Inflammasome-Induced IL-1β Secretion in Microglia Is Characterized by Delayed Kinetics and Is Only Partially Dependent on Inflammatory Caspases.
Actively Induced Experimental Autoimmune Encephalomyelitis in Rats.
Cannabidiol, a non-psychoactive cannabinoid, leads to EGR2-dependent anergy in activated encephalitogenic T cells.
Immunosuppressive potential of human amnion epithelial cells in the treatment of experimental autoimmune encephalomyelitis.
Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain.
Rapid Exercise-Induced Mobilization of Dendritic Cells Is Potentially Mediated by a Flt3L- and MMP-9-Dependent Process in Multiple Sclerosis.
Dissecting the role of E2 protein domains on alphavirus pathogenicity.
Brain activation patterns and cognitive processing speed in patients with pediatric-onset multiple sclerosis.
Rat white matter injury model induced by endothelin-1 injection: technical modification and pathological evaluation.
Pages
« first
‹ previous
…
650
651
652
653
654
655
656
657
658
…
next ›
last »